AstraZeneca (GB:AZN) has released an update.
AstraZeneca’s AMPLIFY Phase III trial has shown positive results, with their Calquence drug in combination with venetoclax, and potentially obinutuzumab, significantly improving progression-free survival in patients with untreated chronic lymphocytic leukaemia (CLL). There was also a favorable trend observed in overall survival rates. These findings could lead to Calquence being the only second-generation BTK inhibitor for both continuous and fixed-duration treatments in CLL, enhancing patient quality of life by allowing treatment breaks.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
